Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2014; 20(42): 15867-15878
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15867
Table 1 Summary of studies included in the meta-analysis
Ref.RegionStudy designYearStudy periodSample size
Level of lymphad-enectomySurgical extensionReconstructionConversionMortality
Matched factors1Quality scores
TLGOGTLGOG
Huscher et al[25]ItalyRCT20051992-19963029D1, D2DB-II, R-YNR3.3%6.7%-32
Pugliese et al[26]ItalyOCS (R)20072000-20054899D2S, TR-Y2.1%2.1%3.0%-7
Song et al[27]South KoreaOCS (P)20082005-20062020D1 + β, D2DB-I, R-Y000-8
Lee et al[28]TaiwanOCS (P)20081998-20053434D2SB-II2.9%0012459
Topal et al[29]BelgiumOCS (R)20082003-20063822D2TR-YNR2.6%4.5%-8
Strong et al[30]United StatesOCS (P)20092005-20083030D2SB-II, R-YNR0012459
Wong et al[31]Hong KongOCS (R)20092001-20061841D1 + α/β, D2DB-II, R-Y5.0%02.4%-7
Chouillard et al[32]FranceOCS (P)20102001-20075179D2D, TB-II, R-Y6.0%02.5%-9
Scatizzi et al[33]ItalyOCS (P)20112006-20093030D2DR-Y6.7%00123459
Moisan et al[34]ChileOCS (R)20122005-20103131D1 + α/β, D2S, TB-II, R-Y3.2%0012459
Cianchi et al[35]ItalyOCS (P)20122008-20124141D1 + α/β, D2S, TB-II, R-Y02.4%4.9%12458
Siani et al[36]ItalyOCS (R)20122003-20092525D1 + α/β, D2TR-Y0001459
Shinohara et al[37]JapanOCS (P)20131998-2008186123D2D, P, TB-I, R-Y2.2%1.1%0123459
Kim et al[38]South KoreaOCS (P)20132011139207D2TR-Y000-7
Table 2 Outcomes of included studies
Ref.Operation timeBlood lossTransfusionRLNProximal marginDistal marginAnalgesic useAmbulationFlatusOral intakeHospital stayMorbidityMortalitySurvival
Huscher et al[25]YYYYYYYY
Pugliese et al[26]YYYY1YYYYYY
Song et al[27]YYYYYY2YYYYY
Lee et al[28]YYYY2YYYY
Topal et al[29]YYYY
Strong et al[30]YYYY1YYYY
Wong et al[31]YYYYYYY
Chouillard et al[32]YYYYYYYY
Scatizzi et al[33]YYY1YYYYYYY
Moisan et al[34]YYYYYYYYYY
Cianchi et al[35]YYYYYYYY
Siani et al[36]YYYYYYYY
Shinohara et al[37]YYYYYYYYYY
Kim et al[38]YYYYY2YYYYY
Table 3 Pooled short-term outcomes
OutcomesNo. of studiesSample size
HeterogeneityOverall effect size95%CI of overall effectP value
TLGOG(P value, I2)
Operation time (min)14721811< 0.001, 97%WMD = 58.0437.77-78.32< 0.001
Blood loss (mL)12552574< 0.001, 87%WMD = -167.57-208.79-(-126.34)< 0.001
Transfusion32682330.11, 54%RR = 0.490.21-1.110.09
Retrieved lymph nodes136837890.04, 46%WMD = -0.48-2.21-1.260.59
Proximal margin (cm)21592270.03, 80%WMD = 0.00-1.47-1.461.00
Distal margin (cm)31902580.03, 70%WMD = 0.94-0.76-(2.64)0.28
Analgesics given (d)31081590.33, 11%WMD = -1.79-2.37-(-1.21)< 0.001
Time to ambulation (d)3264252< 0.001, 93%WMD = -0.91-1.65-(-0.16)0.02
Time to first flatus (d)7337456< 0.001, 98%WMD = -1.97-3.18-(-0.77)0.001
Time to oral intake (d)8525580< 0.001, 96%WMD = -2.39-3.34-(-1.45)< 0.001
Hospital stay (d)13683789< 0.001, 83%WMD = -3.75-4.88-(-2.63)< 0.001
Overall complications147218110.74, 0%RR = 0.710.58-0.86< 0.001
Surgical complications126356900.76, 0%RR = 0.750.57-0.980.03
Medical complications116156700.97, 5%RR = 0.570.38-0.860.008
Mortality74124340.96, 0%RR = 0.650.24-1.760.40
Table 4 Subgroup analysis of learning curve using a cut-point of 40 totally laparoscopic gastrectomy cases
OutcomesNo. of studiesSample size
HeterogeneityOverall effect size95%CI of overall effectP value
TLGOG(P value, I2)
Operation time (min)
< 40 TLG cases9256262< 0.001, 92%WMD = 60.5435.64-85.45< 0.001
> 40 TLG cases5465549< 0.001, 99%WMD = 53.9116.74-91.080.004
Blood loss (mL)
< 40 TLG cases8226232< 0.001, 84%WMD = -155.04-133.22< 0.001
> 40 TLG cases4326342< 0.001, 85%WMD = -194.81-95.98< 0.001
Retrieved lymph nodes
< 40 TLG cases82182400.23, 25%WMD = -1.41-6.110.37
> 40 TLG cases54655490.06, 63%WMD = 0.03-4.270.98
Table 5 Systematic review of postoperative complications and reoperation n (%)
Ref.GroupnTotal eventsLeakageStenosisPulmonaryWoundPancreatitisObstructionCardiovascularBleedingAbscessOtherReoperation
Huscher et al[25]TLG307421NR
OG298152NR
Pugliese et al[26]TLG486123NR
OG991413NR
Song et al[27]TLG20110
OG20110
Lee et al[28]TLG347113112
OG34621210
Topal et al[29]TLG3815121136
OG22910
Strong et al[30]TLG308111311NR
OG30131134121NR
Wong et al[31]TLG183111NR
OG41832111NR
Chouillard et al[32]TLG51912
OG792014
Scatizzi et al[33]TLG30221
OG308131121
Moisan et al[34]TLG31741114
OG314224
Cianchi et al[35]TLG41921121113
OG4114451222
Siani et al[36]TLG254112NR
OG255221NR
Shinohara et al[37]TLG1864415421298
OG1234315510892
Kim et al[38]TLG1391412213325
OG207451491222114NR
Total (%)TLG72113624 (3.4)7 (1.9)13 (2.8)8 (1.7)17 (4.5)12 (4.0)2 (1.6)8 (2.3)11 (2.7)6 (2.0)
OG81119827 (3.4)9 (2.4)28 (4.8)31 (6.3)9 (3.0)9 (2.4)5 (4.0)4 (0.9)23 (5.3)11 (3.0)
P value0.990.630.003< 0.0010.320.230.450.110.060.42
Table 6 Systematic review of long-term survival
Ref.GroupFollow-up (mo)RecurrenceSurvival rate (%)
Huscher et al[25]TLG60 (2-88)115-yr DFS: 57.3, 5-yr OS: 58.9
OG55 (7-90)105-yr DFS: 54.8, 5-yr OS: 55.7
Lee et al[28]TLGNR12NR
OGNR11NR
Song et al[27]TLG114NR2
OG13.85NR2
Wong et al[31]TLG32 (2-79)25-yr OS: 81.0
OG27 (1-79)95-yr OS: 67.5
Chouillard et al[32]TLG29 (12-74)NROS, 1-yr: 88.4, 2-yr: 71.2, 3-y: 43.2
OG33 (14-79)NROS, 1-yr: 88.3, 2-yr: 54.8, 3-yr: 38.4
Scatizzi et al[33]TLG18 (2-37)NR42-mo OS: 70.9
OG18 (7-42)NR42-mo OS: 56.8
Moisan et al[34]TLG2853-yr DFS: 79.4, 3-yr OS: 82.3
OG4043-yr DFS: 83.4, 3-yr OS: 86.9
Siani et al[36]TLG32.6NR5-yr DFS: 54.2, 5-yr OS: 55.7
OG31.9NR5-yr DFS: 52.1, 5-yr OS: 52.9
Shinohara et al[37]TLG48.8(25-58.5)a535-yr DFS: 65.8b, 5-yr OS: 68.1b
OG345-yr DFS: 62.0b, 5-yr OS: 63.7b